Quantcast
Last updated on April 18, 2014 at 0:10 EDT

Latest Abiraterone Stories

2014-04-02 04:21:20

WHIPPANY, N.J., April 2, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced that the company has begun to enroll patients in a trial studying Xofigo(®) (radium Ra 223 dichloride) injection in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients with bone predominant metastatic castration-resistant prostate cancer (mCRPC). The randomized, double-blind, placebo-controlled...

2014-03-27 08:33:33

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/djkgl4/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Newer Oral Anti Androgens - Expanding Role in the Treatment Paradigm of Prostate Cancer" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) In recent past approval and launch of various newer treatment options like Xtandi (Enzalutamide,...

2014-02-24 12:26:47

DALLAS, February 24, 2014 /PRNewswire/ -- ReportsnReports.com offers "Therapeutic Class Overview : Emergence Of Biogenerics Era In Japan - It's Time to Welcome Antibody Biosimilars of Foreign Origins Soon" and "Therapeutic Class Overview: Newer Oral Anti Androgens - Expanding Role in the treatment Paradigm of Prostate Cancer" research reports in its store. Japan biosimilar market will enter new phase of biosimilars with first 'mab' approval expected in 2014. This...

2014-02-20 08:31:11

LONDON, Feb. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 Summary GBI Research has released the pharmaceutical report "Prostate Cancer Therapeutics Market to 2019 - Rising...

2014-02-06 08:28:18

TORONTO, Feb. 6, 2014 /CNW/ - Men with metastatic castration-resistant prostate cancer (mCRPC) in Québec now have access to a therapy that can be used prior to chemotherapy. Effective February 3, 2014, the province has added ZYTIGA(®) (abiraterone acetate) to the public drug formulary for the treatment of mCRPC in men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).(1) "ZYTIGA(® )provides men and health care professionals with a...

2013-12-09 12:27:39

However, the Majority of Surveyed Urologists Have Not Yet Prescribed Xtandi for This Patient Population, According to a New Report from BioTrends Research Group EXTON, Pa., Dec. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at 12 months following the U.S. launch of Medivation/Astellas Pharma's Xtandi for docetaxel-pretreated metastatic castrate-resistant prostate cancer...

2013-11-21 12:27:51

TORONTO, Nov. 21, 2013 /CNW/ - Effective November 15, 2013, British Columbia is the first province to include ZYTIGA(®) (abiraterone acetate) on its public formulary for men living with metastatic prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).(1) Men living with advanced prostate cancer, their caregivers and health care professionals are encouraged to learn more about the specific eligibility criteria that are...

2013-11-19 16:26:06

DALLAS, Nov. 19, 2013 /PRNewswire-iReach/ -- The recent approval of a number of highly effective drugs, including Zytiga and Xtandi, has provided late-stage patients with a number of options and increased survival times by a number of months. These recent approvals are anticipated to generate strong revenues during the forecast following increasing uptake by physicians as the treatment algorithm shifts towards their first-line usage over Taxotere. Additionally, a very large late-stage...

2013-09-28 08:20:24

First study to find patients with unfavorable risk profile at 12 weeks have worse prognosis and should be considered for alternative treatments RARITAN, N.J., Sept. 28, 2013 /PRNewswire/ -- Janssen Diagnostics, LLC announced today results from a study presented at the European Cancer Congress in Amsterdam, Netherlands, that demonstrated circulating tumor cell (CTC) enumeration using CELLSEARCH®, along with lactate dehydrogenase (LDH) as part of a composite biomarker panel, was an...

2013-09-25 11:02:09

Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone. The study, published Sept. 24 in Lancet Oncology, was led by Ethan Basch, MD, director of the Cancer Outcomes Research Program at the University of North Carolina Lineberger Comprehensive Cancer Center. Researchers measured the pain and quality of life...